Search

Search Constraints

You searched for: Author/Creator Recondo, Gonzalo

Search Results

1. 246 Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups. (9th November 2020)

2. 246 Clinicopathologic and genomic correlates of tumor mutational burden and its impact on PD-(L)1 inhibition efficacy in non-small cell lung cancer according to different PD-L1 expression subgroups. (10th December 2020)

3. Access of patients with breast and lung cancer to chemotherapy treatment in public and private hospitals in the city of Buenos Aires. (24th May 2019)

4. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP). Issue 9 (24th July 2020)

5. Argentine consensus recommendations for lung cancer screening programmes: a RAND/UCLA-modified Delphi study. Issue 2 (3rd February 2023)

7. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. (May 2022)

8. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). (2021)